SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/29/24 Lisata Therapeutics, Inc. 10-K 12/31/23 94:55M |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 1.62M 2: EX-10.2 Material Contract HTML 398K 3: EX-10.5 Material Contract HTML 139K 4: EX-19.1 Report Furnished to Security Holders HTML 50K 5: EX-21.1 Subsidiaries List HTML 27K 6: EX-23.1 Consent of Expert or Counsel HTML 25K 9: EX-97 Clawback Policy re: Recovery of Erroneously HTML 33K Awarded Compensation 7: EX-31.1 Certification -- §302 - SOA'02 HTML 28K 8: EX-32 Certification -- §906 - SOA'02 HTML 26K 15: R1 Cover HTML 90K 16: R2 Audit Information HTML 30K 17: R3 Consolidated Balance Sheets HTML 129K 18: R4 Consolidated Balance Sheets (Parenthetical) HTML 38K 19: R5 Consolidated Statements of Operations HTML 101K 20: R6 Consolidated Statements of Comprehensive Loss HTML 60K 21: R7 Consolidated Statements of Equity HTML 92K 22: R8 Consolidated Statements of Cash Flows HTML 97K 23: R9 The Business HTML 40K 24: R10 Summary of Significant Accounting Policies HTML 47K 25: R11 Merger HTML 36K 26: R12 Available-for-Sale-Securities HTML 70K 27: R13 Property and Equipment HTML 36K 28: R14 Income (Loss) Per Share HTML 32K 29: R15 Fair Value Measurements HTML 51K 30: R16 Accrued Liabilities HTML 34K 31: R17 Operating Leases HTML 41K 32: R18 Stockholders' Equity HTML 102K 33: R19 Share-Based Compensation HTML 58K 34: R20 Income Taxes HTML 110K 35: R21 Australia Research and Development Tax Incentive HTML 27K 36: R22 Technology Transfer Agreement HTML 27K 37: R23 Contingencies HTML 28K 38: R24 License Agreements HTML 40K 39: R25 Research Collaboration and License Agreement HTML 40K 40: R26 Pay vs Performance Disclosure HTML 36K 41: R27 Insider Trading Arrangements HTML 30K 42: R28 Summary of Significant Accounting Policies HTML 89K (Policies) 43: R29 Summary of Significant Accounting Policies HTML 37K (Tables) 44: R30 Merger (Tables) HTML 35K 45: R31 Available-for-Sale-Securities (Tables) HTML 72K 46: R32 Property and Equipment (Tables) HTML 37K 47: R33 Income (Loss) Per Share (Tables) HTML 31K 48: R34 Fair Value Measurements (Tables) HTML 47K 49: R35 Accrued Liabilities (Tables) HTML 34K 50: R36 Operating Leases (Tables) HTML 41K 51: R37 Stockholders' Equity (Tables) HTML 91K 52: R38 Share-Based Compensation (Tables) HTML 60K 53: R39 Income Taxes (Tables) HTML 105K 54: R40 The Business (Details) HTML 36K 55: R41 Summary of Significant Accounting Policies - HTML 32K Useful Lives (Details) 56: R42 Summary of Significant Accounting Policies - HTML 52K Narrative (Details) 57: R43 Merger (Details) HTML 52K 58: R44 Available-for-Sale-Securities - Summary (Details) HTML 50K 59: R45 Available-for-Sale-Securities - Classification on HTML 35K Consolidated Balance Sheets (Details) 60: R46 Available-for-Sale-Securities - Contractual HTML 42K Maturities (Details) 61: R47 Property and Equipment - Summary (Details) HTML 39K 62: R48 Property and Equipment - Narrative (Details) HTML 26K 63: R49 Income (Loss) Per Share (Details) HTML 34K 64: R50 Fair Value Measurements (Details) HTML 40K 65: R51 Accrued Liabilities (Details) HTML 37K 66: R52 Operating Leases - Narrative (Details) HTML 30K 67: R53 Operating Leases - Balance Sheet Presentation HTML 40K (Details) 68: R54 Operating Leases - Future Minimum Lease Payments HTML 35K Under Lease Agreements (Details) 69: R55 Stockholders' Equity - Equity Plans (Details) HTML 87K 70: R56 Stockholders' Equity - Equity Issuances (Details) HTML 49K 71: R57 Stockholders' Equity - Stock Options and Warrants HTML 43K Narrative (Details) 72: R58 Stockholders' Equity - Stock Options and Warrants HTML 122K (Details) 73: R59 Stockholders' Equity - Restricted Stock and HTML 43K Restricted Stock Units (Details) 74: R60 Stockholders' Equity - Restricted Stock and HTML 56K Restricted Stock Unit Activity (Details) 75: R61 Share-Based Compensation - Share-Based HTML 31K Compensation Expense (Details) 76: R62 Share-Based Compensation - Narrative (Details) HTML 29K 77: R63 Share-Based Compensation - Compensation Cost Not HTML 43K Yet Recognized (Details) 78: R64 Share-Based Compensation - Fair Value of Shares HTML 38K Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) 79: R65 Share-Based Compensation - Valuation Assumptions HTML 45K (Details) 80: R66 Income Taxes - Loss from Operations Before HTML 34K Provision for Income Taxes (Details) 81: R67 Income Taxes - Components of Benefit from Income HTML 54K Taxes (Details) 82: R68 Income Taxes - Effective Income Tax Reconciliation HTML 49K (Details) 83: R69 Income Taxes - Components of Deferred Income Taxes HTML 58K (Details) 84: R70 Income Taxes - Narrative (Details) HTML 72K 85: R71 Income Taxes - Unrecognized Tax Benefits (Details) HTML 34K 86: R72 Australia Research and Development Tax Incentive HTML 37K (Details) 87: R73 Technology Transfer Agreement (Details) HTML 33K 88: R74 License Agreements (Details) HTML 93K 89: R75 Research Collaboration and License Agreement HTML 44K (Details) 91: XML IDEA XML File -- Filing Summary XML 162K 94: XML XBRL Instance -- lsta-20231231_htm XML 1.39M 90: EXCEL IDEA Workbook of Financial Report Info XLSX 150K 11: EX-101.CAL XBRL Calculations -- lsta-20231231_cal XML 196K 12: EX-101.DEF XBRL Definitions -- lsta-20231231_def XML 509K 13: EX-101.LAB XBRL Labels -- lsta-20231231_lab XML 1.99M 14: EX-101.PRE XBRL Presentations -- lsta-20231231_pre XML 1.11M 10: EX-101.SCH XBRL Schema -- lsta-20231231 XSD 188K 92: JSON XBRL Instance as JSON Data -- MetaLinks 536± 789K 93: ZIP XBRL Zipped Folder -- 0000320017-24-000007-xbrl Zip 877K
ex105esppplancompleteex |
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 2/29/24 | 8-K | ||
For Period end: | 12/31/23 | |||
6/14/23 | 8-K | |||
6/20/18 | 4, 8-K, S-8 | |||
6/30/17 | 10-Q | |||
3/28/17 | ||||
1/1/17 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/14/23 Lisata Therapeutics, Inc. 10-Q 6/30/23 72:8.3M 3/30/23 Lisata Therapeutics, Inc. 10-K 12/31/22 91:49M 9/15/22 Lisata Therapeutics, Inc. 8-K:2,3,5,7 9/14/22 16:8.7M Broadridge Fin’l So… Inc 3/19/21 Lisata Therapeutics, Inc. 8-K:5,9 3/19/21 2:7.2M 2/25/21 Lisata Therapeutics, Inc. 10-K 12/31/20 73:6.6M 2/16/21 Lisata Therapeutics, Inc. 8-K:1,9 2/12/21 7:650K 1/25/21 Lisata Therapeutics, Inc. 8-K:1,3,8,9 1/21/21 5:557K 7/10/20 Lisata Therapeutics, Inc. 8-K:1,3,9 7/10/20 4:481K 5/26/20 Lisata Therapeutics, Inc. 8-K:1,3,9 5/26/20 6:474K 4/24/20 Lisata Therapeutics, Inc. 8-K:1,3,9 4/24/20 6:460K 9/21/17 Lisata Therapeutics, Inc. 8-K:3,5,9 9/18/17 3:148K 8/09/16 Lisata Therapeutics, Inc. 10-Q 6/30/16 78:5.9M |